Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22 (Afternoon) + July 23 (Morning)
China-Europe Healthcare Industry Session
Stay tuned
July 22 (Afternoon)
Conference Planning / Conference Moderation
Andreas Penk:Co-founder & CEO, EBT; Former President of Pfizer China
Fenping Zhang:Chairman&CEO at genOway Shanghai
12:30-13:40 Dinner Reception
14:00-14:20 Opening Address
Alexandre EA:Head of the Lifestyle and Health Division – China / Hong Kong;Co-president of FHA
Olivier Charmeil:Executive Vice President, Sanofi
14:20-14:35 China efficiency:true or false?
Dan Zhang:Co-founder & CSO Shenzhen GrandBay Medical Consulting Company Ltd; Board Member & Chief Strategic Officer ClinChoice Medical Development Ltd; Co-Chairman & Co-founder Hillgene Biopharma Ltd
14:35-14:50 The strategic imperative: partnering in China’s Ecosystem - an MNC perspective
Hong Shen:Head of China Innovation Center of Roche and SVP
14:50-15:05 TBD
Alexandre Fraichard:Founder&CEO at genOway
15:05-15:20 TBD
Jianxin Yang:CEO, Executive Director, President of R&D,
15:20-16:10 Panel Discussion:How Can European Innovative Medicines Benefit from China's Innovation System?
Andreas Penk(Moderation):Co-founder & CEO, EBT; Former President of Pfizer China
Kendra Rose:Senior Vice President and Head of BD&L/OI New Platforms, Cardiovascular and Immunology at Bayer
Lianshan Zhang:EVP&Board member of Jiangsu Hengrui
Harm-Jan Borgeld:Global Head, Asia Partnering at Roche
David Montgomery:co-founders of PM life sciences; Fellows of the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the UK; CEO of PM Life Sciences
David Montgomery:co-founders of PM life sciences; Fellows of the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the UK; CEO of PM Life Sciences
Stefan Platz:Senior Vice President Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca
Xiaobin Wu:Global President and COO, BeOne Medicines
16:10-16:25 TBD
Jun Zhu:Executive Director&CEO at Henlius
16:25-16:40 TBD
Elisabeth Liu:Eximium Asia & Confluence Global Capital CEO
16:40-16:55 TBD
Jenny Yang:Head of External Innovation, Asia Pacific at Novo Nordisk
16:55-17:10 TBD
Xin Xie:Executive Director&SVP of Sino Biopharmaceutical; SVP of CP Group
17:10~18:00 Panel Discussion:Building a Global Innovation Ecosystem Together Through China's New Biopharmaceutical Infrastructure
Fenping Zhang(Moderation):Chairman&CEO at genOway Shanghai
Yingjie Wu:Executive Director, Search & Evaluate, Business Development, Oncology R&D, AstraZeneca
Lihua Yu:COO&SVP of Wuxibiologics
Jeff Duan:Founder&Chairman at PharmaLegacy
Yan Chang:Chairwomen&President at InnoStar Bio
Xiaoou Xu:Chairman at ClinChoice
Zhi Chen:Chairman at Bio-Link
18:00-21:00 Banquet: Closed-Door Exchange Dinner on Innovative Drug Collaboration and Development — When European Depth Meets Chinese Speed
July 23 (Morning)
09:00-09:20 TBD
Wayne Shi:President, Sanofi Greater China
09:20-09:35 TBD
Benedikt Westphalen:Director of the Center for Personalized
edicine at LMU University Hospital Munich;Head of the recision Oncology Program at the Comprehensive Cancer Center Munich
09:35-09:50 TBD
Andreas Föller:Founder&CEO of Cardea
09:50-09:55 Introduction to the UK Faculty of Pharmaceutical Medicine (FPM)
09:55-10:40 Panel Discussion:Embracing Europe to Accelerate China's Biopharmaceutical Innovation
Huini Li(Moderator):Partner/Of Counsel at Adaltys Avocats
Salah-Eddin Al-Batran:CEO of the Frankfurt Institute of Clinical Cancer Research (IKF);Chief Physician at North West Hospital Frankfurt;Board of Directors Member, University Cancer Center Frankfurt, Germany
Edward Jones:CEO of Newmarket Strategy
Ke Shao:Deputy General Manager of Kexing Biopharm
Yaping Shen:Executive President at Hybio
Lijuan Wang:CSO for Chemical Pharmaceuticals at Salubris
Jia Xiao:Sales & Marketing Executive (Life Sciences) at IDA Ireland
10:40-10:55 TBD
Sheuli Porkess:co-founders of PM life sciences;Fellows of the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the UK; President and Chair of the Board of Trustees of the Faculty of Pharmaceutical Medicine;President of the Faculty of Pharmaceutical Medicine from the UK
10:55-11:10 TBD
Bin Li:Distinguished Professor at Shanghai Jiao Tong University
Vice-President of the Shanghai Overseas Returned Scholars Association
Deputy Director of the Shanghai Institute of Immunology
11:10-11:25 TBD
Willy Courtel:CEO of Laboratories Superdiet - URGO Group
11:25-11:40 TBD
Martin Heidecker :CIO of AMR Action Fund
11:40-11:55 TBD
Chih-Yi Hsieh:Global Clinical Development, Asia-Pacific Region Vice President at BioNTech